Kynurenic acid levels are elevated in the cerebrospinal fluid of patients with schizophrenia

被引:374
作者
Erhardt, S
Blennow, K
Nordin, C
Skogh, E
Lindström, LH
Engberg, G [1 ]
机构
[1] Karolinska Inst, Dept Physiol & Pharmacol, S-17177 Stockholm, Sweden
[2] Sahlgrens Univ Hosp, Dept Clin Neurosci, Unit Neurochem, Molndal, Sweden
[3] Linkoping Univ Hosp, Div Psychiat, Dept Neurosci & Locomot, S-58185 Linkoping, Sweden
[4] Univ Uppsala, Vasteras Cent Hosp, Dept Psychiat Res, Vasteras, Sweden
关键词
schizophrenia; kynurenate; glutamate; cerebrospinal fluid; pathogenesis; N-methyl D-aspartate-receptor;
D O I
10.1016/S0304-3940(01)02242-X
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Kynurenic acid is an endogenous glutamate antagonist with a preferential action at the glycine-site of the N-methyl o-aspartate-receptor. Mounting evidence indicate that the compound is significantly involved in basal neurophysiological processes in the brain. In the present investigation, cerebrospinal fluid (CSF) level of kynurenic acid was analyzed in 28 male schizophrenic patients and 17 male healthy controls by means of high pressure liquid chromatography and fluorescence detection. Schizophrenic patients showed elevated CSF levels of kynurenic acid (1.67 +/- 0.27 nM) compared to the control group (0.97 +/- 0.07 nM). Furthermore, CSF levels of kynurenic acid in schizophrenic patients were also found to correlate with age. The present finding is indicative of a contribution of kynurenic acid in the pathogenesis of schizophrenia. (C) 2001 Elsevier Science Ireland Ltd. All rights reserved.
引用
收藏
页码:96 / 98
页数:3
相关论文
共 20 条
[1]   Increased baseline occupancy of D2 receptors by dopamine in schizophrenia [J].
Abi-Dargham, A ;
Rodenhiser, J ;
Printz, D ;
Zea-Ponce, Y ;
Gil, R ;
Kegeles, LS ;
Weiss, R ;
Cooper, TB ;
Mann, JJ ;
Van Heertum, RL ;
Gorman, JM ;
Laruelle, M .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2000, 97 (14) :8104-8109
[2]   Network interactions in schizophrenia - therapeutic implications [J].
Carlsson, A ;
Waters, N ;
Waters, S ;
Carlsson, ML .
BRAIN RESEARCH REVIEWS, 2000, 31 (2-3) :342-349
[3]  
CERESOLIBORRONI G, 1999, SOC NEUR ABSTR, V25, P7278
[4]   Pharmacological elevation of endogenous kynurenic acid levels activates nigral dopamine neurons [J].
Erhardt, S ;
Öberg, H ;
Mathé, JM ;
Engberg, G .
AMINO ACIDS, 2001, 20 (04) :353-362
[5]  
ERHARDT S, 2001, UNPUB ACTA PHYSL SCA
[6]   PHENCYCLIDINE AND THE MIDBRAIN DOPAMINE SYSTEM - ELECTROPHYSIOLOGY AND BEHAVIOR [J].
FRENCH, ED .
NEUROTOXICOLOGY AND TERATOLOGY, 1994, 16 (04) :355-362
[7]   BLOOD-BRAIN-BARRIER TRANSPORT OF KYNURENINES - IMPLICATIONS FOR BRAIN SYNTHESIS AND METABOLISM [J].
FUKUI, S ;
SCHWARCZ, R ;
RAPOPORT, SI ;
TAKADA, Y ;
SMITH, QR .
JOURNAL OF NEUROCHEMISTRY, 1991, 56 (06) :2007-2017
[8]   PHASIC VERSUS TONIC DOPAMINE RELEASE AND THE MODULATION OF DOPAMINE SYSTEM RESPONSIVITY - A HYPOTHESIS FOR THE ETIOLOGY OF SCHIZOPHRENIA [J].
GRACE, AA .
NEUROSCIENCE, 1991, 41 (01) :1-24
[9]   AGE-RELATED-CHANGES IN KYNURENIC ACID PRODUCTION IN RAT-BRAIN [J].
GRAMSBERGEN, JBP ;
SCHMIDT, W ;
TURSKI, WA ;
SCHWARCZ, R .
BRAIN RESEARCH, 1992, 588 (01) :1-5
[10]   QUANTIFICATION OF KYNURENIC ACID IN CEREBROSPINAL-FLUID - EFFECTS OF SYSTEMIC AND CENTRAL L-KYNURENINE ADMINISTRATION [J].
HEYES, MP ;
QUEARRY, BJ .
JOURNAL OF CHROMATOGRAPHY-BIOMEDICAL APPLICATIONS, 1990, 530 (01) :108-115